Bliss GVS Pharma opened lower at ₹626.10, compared with its previous close of ₹632.45. In the last trading session on 6 Nov 2026, the stock traded between ₹613.00 and ₹635.80, with an average traded price of ₹618.86. It showed a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Bliss GVS Pharma is now worth
₹ 60,377.00
giving a profit of
₹ 50,377.00 (503.77%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-18.20 (-2.88%)
Day High
₹635.80
Day Low
₹613.00
Day Open
₹626.10
Prev Close
₹632.45
Volume
76,182
Value Traded
₹4.71 Cr
1W Return
-9.79%
1M Return
-7.60%
3M Return
23.59%
6M Return
127.71%
1Y Return
299.46%
Market Cap (₹ Cr.)
6,528
PE Ratio
40.30
PB Ratio
5.20
Dividend Yield
0.24%
ROE
10.94%
ROCE
16.04%
Book Value (₹)
121.29
Face Value (₹)
1.00
EPS (TTM)
4.92
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-9.79%
6 Weeks
-
1 Month
-7.60%
3 Months
23.59%
9 Months
230.63%
Bliss GVS Pharma pays ₹3.6 lakh fine for board compliance lapse
Paid ₹1,80,000 fine each to BSE and NSE for non-compliance with Regulation 17(1). Violation involved failure to appoint a woman director as required by SEBI rules. Total fine of ₹3.6 lakh constitutes 0.000269% of market capitalisation. Company attributes delayed disclosure to internal coordination issues.
4 days agoBliss GVS subsidiary secures MHRA approval for Mesalazine suppositories
Bliss GVS Pharma's UK subsidiary, Asterisk Lifesciences, received MHRA marketing authorization. The approved product is Mesalazine 1g Suppositories. Authorization allows commercial distribution of the drug in the United Kingdom. Intimation filed under Regulation 30 of SEBI Listing Regulations on November 4, 2026.
6 days agoBliss GVS Pharma declares ₹10 interim dividend; Q2 net profit up 196%
Bliss GVS Pharma declared an interim dividend of ₹10 per equity share for FY27. Standalone net profit rose 196% YoY to ₹7,356.54 lakh in Q2FY27. EBITDA margin expanded to 25.71% from 12.58% in the year-ago quarter. Anupam Rasayan India Limited became the holding company with a 50.07% stake.
8 days agoBliss GVS Pharma seeks shareholder approval for new ESOP plans
Bliss GVS Pharma proposes two new ESOP plans totaling 73,50,000 options. CEO Rahul Adakmol to receive 26,50,000 options under Senior Executive Plan. General Employee ESOP 2026 covers 47,00,000 options for staff and subsidiaries. Exercise price fixed at ₹10 per share for all proposed options. Remote e-voting open from October 29 to November 27, 2026.
13 days agoBliss GVS Pharma seeks shareholder approval for three new directors
Bliss GVS Pharma issued a postal ballot notice for appointing three Non-Executive Non-Independent Directors. Voting period runs from October 16, 2026, to November 14, 2026, via remote e-voting. Appointees Hetul Mehta, Amar Shah, and Pramod Kasat were nominated by new promoters Anupam Rasayan. Cut-off date for eligibility is October 9, 2026; results to be declared by November 17, 2026.
26 days agoBliss GVS Pharma pledges 47.95% equity stake to Catalyst Trusteeship
Pledged 5,09,84,595 equity shares to Catalyst Trusteeship Limited. Encumbrance covers 47.95% of total voting capital. Transaction date recorded as September 30, 2026. Trustee acts on behalf of debenture holders.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,904.50 | -0.55% | ₹4,56,953.35 | 41.80 | +12.60% | |
| ₹11,565.50 | +4.22% | ₹3,07,027.69 | 87.50 | +73.75% | |
| ₹4,780.00 | +0.15% | ₹1,81,815.84 | 86.50 | +33.52% | |
| ₹2,454.00 | +3.54% | ₹1,32,592.62 | 96.10 | +149.86% | |
| ₹1,215.90 | +1.37% | ₹1,21,286.49 | 27.80 | +28.79% | |
| ₹1,385.00 | +1.09% | ₹1,15,603.22 | 41.40 | +14.90% | |
| ₹1,403.80 | -0.14% | ₹1,13,407.17 | 40.00 | -6.77% | |
| ₹2,668.30 | +3.31% | ₹1,10,212.82 | 47.00 | +17.97% | |
| ₹1,855.30 | +2.84% | ₹1,06,749.86 | 26.10 | +65.09% | |
| ₹2,025.00 | +1.40% | ₹92,601.22 | 17.50 | +2.70% | |
| ₹2,671.10 | +2.94% | ₹75,385.03 | 50.50 | +47.45% | |
| ₹5,398.50 | +1.78% | ₹64,547.17 | 28.80 | -4.76% |
An investment of ₹10,000 made 5 years ago in Bliss GVS Pharma is now worth
₹ 60,377.00
giving a profit of
₹ 50,377.00 (503.77%)
Note: Past profits do not guarantee future returns.